NO145437C - Analogifremgangsmaate for fremstilling av en fysiologisk aktiv p-bifenylester av en prostaglandinanalog av e- eller f-serien - Google Patents

Analogifremgangsmaate for fremstilling av en fysiologisk aktiv p-bifenylester av en prostaglandinanalog av e- eller f-serien

Info

Publication number
NO145437C
NO145437C NO4290/73A NO429073A NO145437C NO 145437 C NO145437 C NO 145437C NO 4290/73 A NO4290/73 A NO 4290/73A NO 429073 A NO429073 A NO 429073A NO 145437 C NO145437 C NO 145437C
Authority
NO
Norway
Prior art keywords
physially
bifenylester
preparing
active
series
Prior art date
Application number
NO4290/73A
Other languages
English (en)
Norwegian (no)
Other versions
NO145437B (no
Inventor
Michael Ross Johnson
Thomas Ken Schaaf
Jasjit Singh Bindra
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO145437B publication Critical patent/NO145437B/no
Publication of NO145437C publication Critical patent/NO145437C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • C07D309/12Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/54Quaternary phosphonium compounds
    • C07F9/5407Acyclic saturated phosphonium compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
NO4290/73A 1972-11-08 1973-11-07 Analogifremgangsmaate for fremstilling av en fysiologisk aktiv p-bifenylester av en prostaglandinanalog av e- eller f-serien NO145437C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30481572A 1972-11-08 1972-11-08

Publications (2)

Publication Number Publication Date
NO145437B NO145437B (no) 1981-12-14
NO145437C true NO145437C (no) 1982-03-24

Family

ID=23178143

Family Applications (2)

Application Number Title Priority Date Filing Date
NO4290/73A NO145437C (no) 1972-11-08 1973-11-07 Analogifremgangsmaate for fremstilling av en fysiologisk aktiv p-bifenylester av en prostaglandinanalog av e- eller f-serien
NO743588A NO146280C (no) 1972-11-08 1974-10-03 Bis-tetrahydropyranyleter for anvendelse som mellomprodukt for fremstilling av en fysiologisk aktiv p-bifenylester av en prostaglandinanalog av e- eller f-serien

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO743588A NO146280C (no) 1972-11-08 1974-10-03 Bis-tetrahydropyranyleter for anvendelse som mellomprodukt for fremstilling av en fysiologisk aktiv p-bifenylester av en prostaglandinanalog av e- eller f-serien

Country Status (24)

Country Link
JP (1) JPS5644068B2 (de)
AR (2) AR204816A1 (de)
AT (1) AT347607B (de)
BE (1) BE807047A (de)
CA (1) CA1027559A (de)
CH (1) CH601222A5 (de)
CS (1) CS188175B2 (de)
DD (2) DD113211A5 (de)
DE (2) DE2355042A1 (de)
ES (2) ES420326A1 (de)
FI (1) FI58116C (de)
FR (2) FR2205339B1 (de)
GB (1) GB1456511A (de)
HU (2) HU171945B (de)
IE (1) IE39686B1 (de)
IL (1) IL43553A (de)
IN (1) IN139905B (de)
NL (1) NL7315240A (de)
NO (2) NO145437C (de)
PH (2) PH15504A (de)
SE (2) SE420198B (de)
SU (2) SU538659A3 (de)
YU (2) YU287973A (de)
ZA (1) ZA738593B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2361381A1 (fr) * 1972-07-13 1978-03-10 Pfizer Ethers tetrahydropyranyliques, utiles comme intermediaires de synthese de prostaglandines
US3929862A (en) * 1974-01-08 1975-12-30 Upjohn Co Substituted tolylesters of PGF{HD 2{B {60
US3998869A (en) * 1974-11-14 1976-12-21 The Upjohn Company Substituted anilide esters of 16-substituted PGE2
DE2737807A1 (de) * 1976-08-27 1978-03-09 Pfizer C tief 1 -p-biphenylester von omega-pentanorprostaglandinen
US6531504B2 (en) * 2001-05-17 2003-03-11 Allergan, Inc. Prostanoic acid derivatives as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
DE2365999A1 (de) 1977-05-12
IL43553A (en) 1979-10-31
AR204816A1 (es) 1976-03-05
NL7315240A (de) 1974-05-10
ATA937173A (de) 1978-05-15
IN139905B (de) 1976-08-14
JPS49100060A (de) 1974-09-20
PH13794A (en) 1980-10-01
NO145437B (no) 1981-12-14
HU171945B (hu) 1978-04-28
CS188175B2 (en) 1979-02-28
AT347607B (de) 1979-01-10
SU1021340A3 (ru) 1983-05-30
IL43553A0 (en) 1974-03-14
YU287973A (en) 1982-02-25
AU6222573A (en) 1975-05-08
FR2275452B1 (de) 1977-12-16
NO743588L (no) 1974-05-09
FR2205339B1 (de) 1980-01-04
CA1027559A (en) 1978-03-07
IE39686L (en) 1974-05-08
PH15504A (en) 1983-02-03
ES420326A1 (es) 1976-03-16
NO146280B (no) 1982-05-24
JPS5644068B2 (de) 1981-10-16
BE807047A (fr) 1974-05-08
FR2205339A1 (de) 1974-05-31
FR2275452A1 (fr) 1976-01-16
HU171818B (hu) 1978-03-28
IE39686B1 (en) 1978-12-06
DD113211A5 (de) 1975-05-20
FI58116B (fi) 1980-08-29
GB1456511A (en) 1976-11-24
FI58116C (fi) 1980-12-10
SU538659A3 (ru) 1976-12-05
SE420198B (sv) 1981-09-21
NO146280C (no) 1982-09-01
DD111370A5 (de) 1975-02-12
YU264480A (en) 1983-04-27
ES434687A1 (es) 1976-12-16
DE2355042A1 (de) 1974-05-22
CH601222A5 (de) 1978-06-30
AR202311A1 (es) 1975-05-30
ZA738593B (en) 1974-10-30
SE7704369L (sv) 1977-04-15

Similar Documents

Publication Publication Date Title
NO139072C (no) Fremgangsmaate for fremstilling av et forprodukt for kjaeledyr
NO139689C (no) Fremgangsmaate for fremstilling av lateks
NO157933C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme cefemforbindelser.
NO144223C (no) Fremgangsmaate til fremstilling av strekkbart papir
NO143663C (no) Analogifremgangsmaate for fremstilling av en fysiologisk aktiv prostaglandinforbindelse av e- eller f-serien
SE410447B (sv) Halogenacetonilider for paverkan av tillvexten av vexter
SE390114B (sv) Forfarande for forangning av en vetska
SE448992B (sv) Forfarande for framstellning av en omega-pentanorprostaglandin ur e- eller f-serierna
SE399423B (sv) Forfarande for framstellning av prostaglandinanaloger
NO153573C (no) Analogifremgangsm¨te for fremstilling av terapeutisk aktiv e n-acylamino-alfa-arylacet-amidocefalosporiner.
NO142033C (no) Analogifremgangsmaate for fremstilling av nye terapeutisk aktive isopropylamino-3-fenoksypropanoler
NO140478C (no) Fremgangsmaate for fremstilling av fibriller
SE392609B (sv) Forfarande for framstellning av metanhaltiga gaser
NO144830C (no) Substituert cyklopentanderivat for anvendelse som mellomprodukt ved fremstilling av en fysiologisk aktiv prostaglandinforbindelse av e- eller f-serien
SE397201B (sv) Forfarande for framstellning av glukosisomeras fran en mikroorganism av slektet actionoplanes
NO145437C (no) Analogifremgangsmaate for fremstilling av en fysiologisk aktiv p-bifenylester av en prostaglandinanalog av e- eller f-serien
SE7609048L (sv) Forfarande for framstellning av prostaglandiner
SE404525B (sv) Forfarande for framstellning av 4-aminometyl-cyklohexan-karboxylsyra-1
SE403108B (sv) Forfarande for framstellning av ett flavanonderivat ur ett av lakritsrot utvunnet utgangsmaterial
SE385123B (sv) Sett att framstella racemisk eller optiskt aktiv 13beta-etyl-17alfa-etynyl-gon-4-en-3-on-17beta-ol
FI56670B (fi) Foerfarande foer framstaellning av 5-cyklohexyl-6-halogenindan-1-karboxylsyraderivat
SE398500B (sv) Forfarande for framstellning av 2-(3-legre alkylamino-2-hydroxipropyl)-3-fenylpyrazin
DK551178A (da) Analogifremgangsmaade til fremstilling af prostaglandin-analoge
SE395005B (sv) Forfarande for framstellning av 1-arylidenamino-4-(2-oxo-3-fenyl-3-bensofuryl)-piperaziner
SE401784B (sv) Anvendning av omega-klor-omega-isonitrosoacetonfenon som baktericid